causal

IRA Shifted Investment Away From Small-Molecule Oncology

Because the IRA shortens revenue duration, most investment firms have shifted dollars away from small-molecule oncology, since five years at the tail of a product can represent half of an asset's NPV and cancer drugs need long trials to move to frontline use.

causalpending

Speaker

Rod

Evidence Quote

“most firms have shifted dollars away from oncology and specifically small molecules because of the law.”

Source

RTW: Investing Across Healthcare— Business Breakdowns
Created: 11/13/2026, 1:54:32 PM

Your notes

Loading notes...